<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82494">
  <stage>Registered</stage>
  <submitdate>27/12/2007</submitdate>
  <approvaldate>5/03/2008</approvaldate>
  <actrnumber>ACTRN12608000121369</actrnumber>
  <trial_identification>
    <studytitle>A trial of inhaled heparin in patients with acute lung injury</studytitle>
    <scientifictitle>A phase 2 randomised blinded trial of nebulised heparin in patients requiring mechanical ventilation for more than 48 hours</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Acute lung injury</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Inhaled heparin (5 ml) will be given daily for 14 days or until extubation</interventions>
    <comparator>Nebulised normal saline 5ml will be given daily for 14 days or until extubation</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Arterial to inspired oxygen ratio will be measured by assessing the oxygen level in a arterial blood sample</outcome>
      <timepoint>Daily for up to 14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events</outcome>
      <timepoint>Daily for up to 14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Has or at high risk of developing acute lung injury</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>At risk of pulmonary hemorrhage
Allergy to heparin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/04/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3065</postcode>
    <postcode>3065</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St.Vincent's Health</primarysponsorname>
    <primarysponsoraddress>41 Victoria Pde
Fitzroy VIC 3065</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Intensive Care Foundation</fundingname>
      <fundingaddress>Ievers St
Carlton Melbourne VIC</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate if nebulised heparin improves oxygenation of patients with acute lung injury</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St.Vincent's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/02/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>008/08</hrec>
      <ethicsubmitdate>2/02/2008</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St. Vincent's Health
41 Victoria Pde
Fitzroy Melbourne VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax />
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St. Vincent's Health
41 Victoria Pde
Fitzroy Melbourne VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax />
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St. Vincent's Health
41 Victoria Pde
Fitzroy Melbourne VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax>+61 3 92884497</fax>
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>